History of allergic reactions attributed to compounds of similar chemical or biologic composition to ipilimumab, nivolumab, or other agents used in study, or history of severe hypersensitivity reaction to any monoclonal antibody
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 (pembrolizumab) and/or rhIL-12 or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition as the study agents
Patients must not have history of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab or other agents used in the study
History of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to the taselisib drug formulation or other agents used in this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ficlatuzumab or other agents used in study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to BL-8040, G-CSF, or other agents used in the study.
Subject has history of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide or other agents used in the study.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to eribulin or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to talazoparib (BMN 673) or other agents used in study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin, nab-paclitaxel, or other agents used in the study; previous grade 1 or 2 allergic reaction to cetuximab is permissible
History of allergic reactions attributed to compounds of similar chemical or biologic composition to liposomal cytarabine or other agents used in study inclusive of known allergy to polyethylene glycol
History of allergic reactions attributed to compounds of similar chemical or biologic composition to PD 0332991or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in study
History of allergic reactions attributed to compounds of similar chemical composition to chemotherapy to be used in this study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to monoclonal antibody treatment, any components used in the ramucirumab drug product (DP) preparation, irinotecan, or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib or ganitumab or other agents used in study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents (cyclophosphamide, busulfan, pentostatin, sirolimus, MMF, granulocyte-colony stimulating factor [G-CSF]) used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents used in this study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to defactinib, pembrolizumab, gemcitabine, or other agents used in the study
History of severe, immediate hypersensitivity reaction attributed to compounds of similar chemical or biologic composition to any agents used in study or in the manufacturing of the cells (i.e. gentamicin)
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to carfilzomib or other agents (R-CHOP) used in this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to PTX-200 or other agents used in the study (e.g., imidazoles, quinolones)
Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to carfilzomib or lenalidomide agents used in study, such as bortezomib or thalidomide, in addition to patients with known allergy to sulfobutyl ether beta-cyclodextrin (Captisol)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Combotox or other agents used in study agents
History of allergic reactions attributed to compounds of similar chemical or biologic composition to (study agent) or other agents used in study
History of allergic reactions attributed to compound of similar chemical or biologic composition to the agents used in this study.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide, CRLX101, or other agents used in study.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agents to be used in the cohort the subject will be enrolled into
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to ADI-PEG 20, gemcitabine, pegylated compounds, or other agents used in the study
History of severe, immediate hypersensitivity reaction attributed to compounds of similar chemical or biologic composition to any agents used in study or in the manufacturing of the cells
Has a history of allergic reactions attributed to the study treatments (AZD9150 or durvalumab), assigned chemotherapy agents, their compounds, or agents of similar chemical or biologic composition (e.g., antibody therapeutics)
COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: History of allergic reactions attributed to compounds of similar chemical or biologic composition to imipridones or other agents used in study
COHORT 2: TRIPLE NEGATIVE BREAST CANCER: History of allergic reactions attributed to compounds of similar chemical or biologic composition to imipridones or other agents used in study
COHORT 3: ENDOMETRIAL CANCER: History of allergic reactions attributed to compounds of similar chemical or biologic composition to imipridones or other agents used in study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pevonedistat, ruxolitinib, or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide and blinatumomab or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin, carboplatin and paclitaxel or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to leuprolide acetate, abiraterone acetate, prednisone or apalutamide or other agents used in the study.
History of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to avelumab or other agents used in the study (or monoclonal antibodies)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Vicinium or durvalumab or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to blinatumomab or pembrolizumab or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-paclitaxel, carboplatin, pembrolizumab, or other agents used in this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to the chemotherapy agents in this study (if necessary)
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide, decitabine or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib and blinatumomab or other agents used in this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine or other agents used in study
History of allergic reactions attributed to compounds of chemical or biologic composition similar to interferons or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib, letrozole, trastuzumab, any other aromatase inhibitor, any other monoclonal antibody, or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biological composition to rebastinib or other agents used in the study (e.g., Cremophor)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cesium 131 or other agents used in this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to talimogene laherparepvec or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent or other agents used in the study
PHASE I AND II SCLC AND UROTHELIAL CARCINOMA EXPANSION COHORT: History of allergic reactions attributed to compounds of similar chemical or biologic composition to CRLX101 and/or olaparib or other agents used in study
History of severe allergic reactions attributed to compounds of similar chemical or biologic composition as obinutuzumab or ibrutinib or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to methotrexate, vinblastine, doxorubicin or cisplatin or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to DHEA or other agents used in the study
History of allergic reactions attributed to thalidomide, lenalidomide, or other compounds of similar chemical or biologic composition to pomalidomide or other agents used in study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin, methotrexate, gemcitabine or other agents used during the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to BVD-523, gemcitabine, nab-paclitaxel, or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to dexrazoxane or other agents used in the study
PHASE I: History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib or tremelimumab, or other agents used in study
PHASE II: History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib or tremelimumab, or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to (study agent) or other agents used in study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to indoximod, docetaxel, or other agents used in the study.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABRAXANE or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to doxorubicin or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to mitomycin C or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cetuximab or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to nintedanib or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to doxorubicin or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine and or busulfan or other agents used in this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or other agents used in this study
History of allergic reactions attributed to compounds of similar chemical composition agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to anakinra or other agents used in study; known hypersensitivity to Chinese hamster ovary (CHO)-cell derived biologics or any components of anakinra
History of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the experimental agents or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to agent(s) or other agents used in study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to vorolanib, nivolumab, or pembrolizumab (as applicable), any monoclonal antibody, or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to BMS-813160, nivolumab, gemcitabine, paclitaxel, nab-paclitaxel, or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to poly-ICLC or other agents used in the study.
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to MCS110, doxorubicin, cyclophosphamide, paclitaxel, or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to regorafenib or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib and AT13387 used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib or other agents used in this study
History of allergic reactions attributed to compounds of similar chemical or biological composition to other agents used in this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to PLX3397 or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244 or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cetuximab or cisplatinum or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ethacrynic acid or other agents used in study
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or other agents used in study, including Cremophor, carboplatin, paclitaxel, cisplatin, 5-fluorouracil, hydroxyurea, or any compounds of similar chemical or biologic composition are not eligible
History of allergic reactions attributed to compounds of similar chemical or biologic composition ipilimumab or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib or other agents used in the study
Patients must NOT have history of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib or other agents used in the study
PHASE II: Patients must NOT have history of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib or other agents used in the study
History of severe, immediate hypersensitivity reaction attributed to compounds of similar chemical or biologic composition to any agents used in study or in the manufacturing of the cells (i.e. gentamicin)
History of allergic reactions attributed to compounds of similar chemical or biologic composition of those used in this study
Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to trametinib or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to IL-12 or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib (ABT-888) or cyclophosphamide used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to PD 0332991, cetuximab, or other agents used in the study
Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888, carboplatin, paclitaxel or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide, fludarabine, or other agents used in the study.
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI4736 or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to poly-ICLC or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to the agents used in the study
History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to rituximab or other agents used in this study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to rituximab, cytarabine, bendamustine or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to GEN-1 or other agents used in this study.
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to KPT-330 or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to everolimus or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to tosedostat or capecitabine or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pacritinib or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine or nab-paclitaxel or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to curcumin or vitamin D or other agents used in this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pomalidomide (e.g. lenalidomide, thalidomide) or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to dabrafenib or other agents used in this study
Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to dabrafenib or other agents used in this study including dimethyl sulfoxide (DMSO)
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to doxorubicin or other agents used in the study
Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib, cetuximab, or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to the chemotherapy used in the study
Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to either MLN8237 or nab-paclitaxel, or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to AMG 386 or the anti-VEGF agent used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ofatumumab or other agents used in study
Subjects with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to sonidegib or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide or other agents used in the study.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in study
History of allergic reactions attributed to compounds similar in chemical or biological composition to vorinostat or other agents used in this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ganetespib or other agents used in study; history of severe allergic or hypersensitivity reactions to taxanes
History of allergic reactions attributed to compounds of similar chemical or biologic composition to entinostat, azacitidine, mannitol, irinotecan, docetaxel, pemetrexed, or gemcitabine, or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Sunphenon 90 DCF-T or other agents used in this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to 3-AP (triapine) or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to tretinoin or lithium carbonate or other agents used in this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-2206 or other agents used in this study
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin and paclitaxel or other agents used in the study are excluded
History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide, gemcitabine or carboplatin, or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to sEphB4-HSA or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib, nivolumab, ipilimumab or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to calcitriol, ketoconazole, or other agents used in study
History of allergic reactions attributed to compound of similar chemical or biologic composition to the agent(s) used in this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to the agent used in study.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Abraxane (paclitaxel albumin-stabilized nanoparticle formulation) or other agents used in this study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pacritinib or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MVA-brachyury-TRICOM or other agents used in study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to melphalan HCl for injection (propylene glycol-free), Captisol, or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pomalidomide, everolimus, or other agents used in the study
Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to levocetirizine, capecitabine, bevacizumab, or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to PXD-101 or Zevalin or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agents used in study (including hypersensitivity to paclitaxel, Cremophor, or platins)
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to rociletinib or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to BMN 673 and AT13387 used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pacritinib or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to melphalan, cyclophosphamide, or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pemetrexed (pemetrexed disodium), 5-FU (fluorouracil), leucovorin (leucovorin calcium) or oxaliplatin, or other agents used for premedication in the study
Subject has history of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide or other agents used in the study.
Subjects with known hypersensitivity or other allergic reactions attributed to compounds of similar biologic composition to netupitant, palonosetron, dexamethasone, or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin, docetaxel, doxorubicin, cyclophosphamide, paclitaxel, or other agents used in the study
Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to brentuximab vedotin or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin or other agents used in study
History of allergic reactions attributed to compounds of similar chemical composition to the study agents
History of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ferumoxytol or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ferumoxytol or other agents used in the study
History of allergic reactions to IV contrasts or reactions attributed to compounds of similar chemical or biologic composition to Ga-68-DOTA-TOC or 18F-FLT used in study
Women with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to isosulfan blue or indocyanine green or other agents used in this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or other agents used in study
